Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-Infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-Tuberculous Therapy

Next Previous
X
Search
Trial Profile

Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-Infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-Tuberculous Therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nevirapine (Primary) ; Lamivudine; Lamivudine/stavudine/nevirapine; Rifampicin; Stavudine
  • Indications HIV infections; Tuberculosis
  • Focus Pharmacokinetics

    • Most Recent Events

    • 03 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 03 Dec 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2008 Planned start date changed from Feb 2008 to May 2008 according to clinicaltrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top